Thursday 15 October 2026
Export ELDN’s income statement to Excel — free account
Eledon Pharmaceuticals, Inc.
ELDN Healthcare Biotechnology
In the quarter to June 2026, EPS fell 107.7% and free cash flow fell 28.0%, each against the same quarter a year earlier.
2.27
0.02
+0.89%
Follow ELDN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
6.74 | 7.40 | 8.44 | 7.90 |
Net Debt/EBITDA |
4.90 | 6.21 | 5.24 | 3.88 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.83 | 1.35 | 0.58 | 0.72 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.19) | (0.17) | (0.20) | (0.20) | |
Cash per Share |
1.21 | 1.63 | 0.99 | 0.78 | |
Shareholders Equity per Share |
1.18 | 1.67 | 0.89 | 0.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.18 | 1.67 | 0.89 | 0.63 | |
Free Cash Flow |
(14.48) | (14.09) | (22.61) | (22.68) | |
Working Capital |
82.01 | 117.34 | 100.12 | 81.30 | |
Net Current Asset Value |
57.50 | 103.46 | 67.37 | 39.03 | |
| Other line items | |||||
Quick Ratio |
6.53 | 7.27 | 8.25 | 7.53 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.19) | (0.17) | (0.20) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.24 | 4.73 | 4.74 | 4.52 | |
Average Assets |
122.22 | 173.21 | 153.99 | 135.50 | |
Average Common Equity |
55.71 | 71.77 | 51.83 | 41.67 |
Columns are period end dates